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Abstract
A growing body of evidence suggests a role for soluble alpha-amyloid precursor protein (sAPPalpha) in pathomechanisms
of Alzheimer disease (AD). This cleavage product of APP was identified to have neurotrophic properties. However, it
remained enigmatic what proteins, targeted by sAPPalpha, might be involved in such neuroprotective actions. Here, we
used high-resolution two-dimensional polyacrylamide gel electrophoresis to analyze proteome changes downstream of
sAPPalpha in neurons. We present evidence that sAPPalpha regulates expression and activity of CDK5, a kinase that plays an
important role in AD pathology. We also identified the cytoprotective chaperone ORP150 to be induced by sAPPalpha as
part of this protective response. Finally, we present functional evidence that the sAPPalpha receptor SORLA is essential to
mediate such molecular functions of sAPPalpha in neurons.
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Introduction
Amyloid precursor protein (APP) is a major etiologic agent in
Alzheimer disease (AD). Amyloidogenic processing of APP by
beta- and gamma-secretases generates Amyloid-beta (Abeta), the
main component of senile plaques. Accumulating evidence
supports the notion that progression of AD is correlated with
progressive accumulation of Abeta in the brain which can be
caused by elevated production and aggregation or impaired
clearance of the peptide [1]. More recently, a growing body of
evidence also implicated another APP cleavage product, soluble
alpha-APP (sAPPalpha), in AD pathology. This product is
produced from APP by an alternative, non-amyloidogenic
processing pathway and levels of sAPPalpha were shown to be
reduced in the cerebrospinal fluid of humans with sporadic or
familial AD [2–4].
Important evidence for a central function of sAPPalpha in the
brain was provided by studies with mice deficient for APP and
APLP2, an APP homolog with overlapping functions. Perinatal
lethality as well as other phenotypical abnormalities of APP/
APLP2 double knockout mice were rescued by a sAPPalpha
transgene [5]. Furthermore, if infused into the brains of rodents,
sAPPalpha enhanced synaptogenesis and memory formation
[6,7]. Other studies reported enhanced survival of cells and
neurite outgrowth after application of sAPPalpha to cultured
cortical and hippocampal neurons [8–11] and other cell types
[12–14]. Together, sAPPalpha was proposed to have neuro-
trophic and neuroprotective properties, possibly counteracting
neurotoxic effects of Abeta. Accordingly, loss of sAPPalpha as
observed in AD patients might contribute to disease pathology.
After cleavage of APP by alpha-secretase, sAPPalpha is released
into the extracellular space in a process that was reported to be
coupled to synaptic activity [15]. Only little is known about
mechanisms controlling receptor-mediated uptake and down-
stream signalling of sAPPalpha in neurons. However, recent
evidence suggested that sorting protein-related receptor containing
LDLR class A repeats (SORLA; also known as LR11), an
important AD risk factor, may act as sAPPalpha receptor [16,17].
Here, we have used high-resolution two-dimensional polyacryl-
amide gel electrophoresis to determine proteins altered in
expression after sAPPalpha application to primary cortical mouse
neurons. We show that sAPPalpha regulates expression and
activity of cyclin-dependent kinase 5 (CDK5), a kinase that plays
an important role in AD pathology and that was previously shown
to be activated by Abeta. We also identified hypoxia up-regulated
protein 1 (ORP150) as effector protein potentially mediating
neuroprotective functions of sAPPalpha. Finally, we present
functional evidence that the sAPPalpha receptor SORLA deter-
mines these molecular functions of sAPPalpha.
Materials and Methods
Ethics Statement
All experiments performed with mice were conducted according
to the guidelines of the German Animal Welfare Law. The study
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was approved by the State Office of Health and Social Affairs
Berlin (approval number T0297/01).
Preparation and Treatment of Primary Neurons
Primary cortical neurons were prepared from newborn Balb/
c mice of either sex at postnatal day 1. Cortices were
dissociated in papain (1 hour at 37uC) and cultured on poly-
D-lysine/collagen coated culture dishes. The neurons were
cultured for 4–5 days in Neurobasal-A medium (Gibco)
including B27 supplement (Sigma), and GlutaMAX (Invitrogen)
as previously described [18].
Neurons were treated with human recombinant neuron-specific
sAPPalpha (APP isoform 695) produced in E. coli (SIGMA; for
proteome analysis) or Leishmania tarentolae (for Western blot
analysis) prepared as described before [19]. Neurons were supplied
with sAPPalpha (300 ng/ml) or medium only (control) for one
hour or 48 hours, respectively, by replacing half of the culture
medium with fresh medium. For proteome analyses, the cells were
harvested in ice cold PBS and cell pellets were frozen immediately
in liquid nitrogen. Six individual samples of each, treated and
control cells were collected for each condition (n= 6). Generation
of animals genetically deficient for Sorl12/2 has been described
before [20].
For detection of sAPPalpha, human specific monoclonal
antibody (clone 2B3, IBL Hamburg), which recognizes the C-
terminus of human sAPPalpha (DAEFRHDSGYEVHHQK) was
used. All other antisera have been obtained from Cell Signaling
Technology. Western blotting was conducted according to
standard procedures. Protein signals were measured with a CCD
camera based chemiluminescence imaging system (Peqlab).
Quantification of signal intensities was accomplished with ImageJ
software and significance of changes was determined applying
Mann-Whitney-U test (p#0.05) using Prism (version 5.0c,
GraphPad).
Protein Extraction and 2-D Electrophoresis
For proteome analyses, the cells were harvested in ice cold
PBS. Six individual samples of each treated and control cells
were collected (n = 6). Protein extracts were prepared from
frozen cell pellets as described [21]. Briefly, samples together
with sample buffer (50 mM TRIZMA Base (Sigma-Aldrich),
50 mM KCl and 20% w/v glycerol at pH 7.5) as well as
proteinase and phosphatase inhibitors (Complete and PhosStop,
Roche Diagnostics) were ground to fine powder in liquid
nitrogen and sonicated on ice subsequently. Afterwards, DNAse
(Benzonase, Merck), urea and thiourea (Biorad; 6.5 M and 2 M,
respectively) were added. Protein extracts were then supplied
with 70 mM dithiothreitol (Biorad), 2% v/w of ampholyte
mixture (Servalyte pH 2–4, Serva) and stored at 280uC until
separation by 2-D electrophoresis.
High-resolution, large-gel 2D-electrophoresis was described
previously [22]. The gel format was 40 cm (isoelectric focu-
sing)630 cm (SDS-PAGE)60.9 mm (gel width). Proteins were first
separated according to their isoelectric points (isoelectric focussing,
IEF) using the carrier-ampholyte technique [21,22]. 40 mg of
protein was applied to the acidic end of IEF gels (40 cm) and a
carrier ampholyte mixture was added to establish a pH gradient
spanning a range from pH 3 to 10. For SDS-PAGE, IEF gels were
cut in half and run as ‘‘acidic’’ and ‘‘basic’’ sides. Two-dimensional
protein patterns were obtained by sliver staining of gels as
described [22]. The 2-D images were scanned at 300 dpi and 16-
bit gray scale and saved in Tiff format to avoid loss of quality due
to compression.
Protein spot patterns were evaluated using Delta2D imaging
software (version 4.0, Decodon). Percent volume of spot pixel
intensities was used for quantitative analysis of protein expression
by Delta2D as described before [21]. Paired Student’s t-test was
applied to determine statistical significance of alterations (signif-
icance threshold p#0.05) as described before [21,23]. Only fold
changes exceeding 20% were considered.
Mass Spectrometry
For protein identification, 1200 mg protein extract each was
separated on a 2-D gel and stained with a MS-compatible silver
staining protocol [22]. Protein spots of interest were excised
from gels and subjected to in-gel tryptic digestion followed by
HPLC separation as described [22]. Peptides were characterized
by an ESI-tandem-MS/MS on a LCQ Deca XP ion trap
instrument (Thermo Finnigan, Waltham, MA). Mass spectra
were evaluated using MASCOT (version 2.1) automatically
searching SwissProt database (version 51.8/513877 sequences).
MS/MS ion search was performed with the following set of
parameters: (i) taxonomy: Mus musculus, (ii) proteolytic enzyme:
trypsin, (iii) maximum of accepted missed cleavages: 1, (iv) mass
value: monoisotopic, (v) peptide mass tolerance 0.8 Da, (vi)
fragment mass tolerance: 0.8 Da, (vii) fixed modifications: none
and (viii) variable modifications: oxidation of methionine and
acrylamide adducts (propionamide) on cysteine. Only proteins
with scores corresponding to p,0.05, with at least two
independent peptides identified were considered. The cut-off
score for individual peptides was equivalent to p,0.05 for each
peptide as calculated by MASCOT.
Results
Proteome Analysis of Murine Neurons Treated with
sAPPalpha
Cumulative evidence suggests neurotrophic properties of
sAPPalpha [6–11,24,25]. However, little is known about the
underlying molecular mechanisms. We performed high-resolu-
tion 2-D electrophoresis (2-DE) combined with mass spectrom-
etry to screen for proteins altered downstream of sAPPalpha
signalling in neurons. This 2-DE based approach allowed us to
simultaneously quantify expression levels of several modified
forms of the same protein as these appear as separate spots on
2-D gels allowing separate quantification. This aspect deemed
particularly important as neurotrophic factors often induce
changes in post-translational modification of target proteins such
as phosphorylation [19,26].
Primary cortical neurons of mice were treated with sAPPalpha
and proteome alterations following this treatment were deter-
mined by statistic evaluation of protein intensity signals on silver-
stained 2-D gels using Delta2D software. In detail, cortical
neurons were prepared from newborn mice and differentiated in
culture for 4 days. Six individual preparations of primary neurons
were compared in every group (n= 6, biological replicates) and
every treatment condition was compared to controls (neurons
treated with medium only). Recombinant sAPPalpha was applied
to the cell culture media at a concentration of 300 ng/ml. The
applied sAPPalpha concentration was described before to induce
ERK phosphorylation in neurons [19] and to increase levels of
neuroprotective genes when applied to organotypic hippocampal
slice cultures [25].
We treated neurons for one hour and 48 hours, respectively, to
cover acute as well as long-term effects. Comparison of treated
versus control neurons revealed that 99 protein spots were
significantly altered after one hour of sAPPalpha treatment and
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47 protein spots were significantly altered after 48 hours of
treatment. Nine proteins were altered under both treatment
conditions (paired Student’s t-test, p#0.05, ratio cut-off $20%;
Figure 1A).
Together, proteome analysis revealed a large number of acute
protein alterations after sAPPalpha treatment. A lower number of
proteins were altered under chronic conditions.
Reduced Expression of CDK5 and Altered Expression of
CDK5 Associated Proteins in Neurons Treated with
sAPPalpha
In order to identify significantly altered proteins, corresponding
protein spots were excised from 2-D gels and identified by mass
spectrometry (Table S1). We were most interested in proteins
altered under both treatment conditions, as these proteins are most
likely particularly relevant to sAPPalpha function. Among proteins
altered under both treatment conditions, five proteins could be
identified by mass spectrometry. These proteins were collapsin-
response mediator protein 2 (CRMP2), histone H2B, hypoxia up-
regulated protein 1 (ORP150), beta-tubulin and cyclin-dependent
kinase 5 (CDK5). Expression of protein spots corresponding to
CRMP2 and ORP150 was up-regulated and expression of spots
corresponding to CDK5, histone H2B, and beta-tubulin was
down-regulated in treated neurons.
Interestingly, CDK5 and CRMP2 were previously associated
with AD pathology [27,28]. Moreover, CRMP2, histone H2B,
and beta-tubulin interact with CDK5 [27,29,30]. CDK5 plays a
critical role in AD pathomechanisms as CDK5 phosphorylates
APP, tau, and BACE1, affecting both hallmarks of AD, amyloid
and tau pathology [31]. We therefore decided to analyze CDK5 as
sAPPalpha target in more detail.
Using Western blot analysis of primary cortical neurons, we
confirmed down-regulation of CDK5 expression after acute as
well as long-term treatment with sAPPalpha (Figure 1 C).
Moreover, 24% of proteins altered after sAPPalpha treatment
(Table S1) are known CDK5 associated proteins (13 out of 55 non-
redundant identified proteins; Table 1).
Together, identification of altered proteins revealed that CDK5
might be the key downstream mediator of sAPPalpha signaling in
neurons.
CDK5 as well as CDK5 Associated Proteins are not
Regulated by sAPPalpha in Neurons Lacking SORLA
SORLA is documented to be an intracellular trafficking
receptor regulating APP processing [32]. SORLA directly binds
to APP within the d6 domain, which is also an integral part of
sAPPalpha [17]. Recent evidence demonstrated that SORLA also
binds and mediates internalization of sAPPalpha in neurons [16].
As SORLA is the best-known receptor for sAPPalpha in neurons,
we analyzed whether the observed molecular effects of sAPPalpha
were dependent on this receptor.
First, we analyzed whether SORLA mediates uptake of
recombinant sAPPalpha in our experimental setup. Thus, we
treated primary cortical neurons derived from either wild-type or
Sorl1 (the gene coding for SORLA)-deficient mice with sAPPalpha
for one hour and quantified the amounts of intracellular
recombinant sAPPalpha after treatment. In accordance with the
previous study, we found a significant reduction of sAPPalpha
signal intensity (about 50%) in Sorl1-deficient neurons as compared
to wild-type neurons (Figure 2 A & B). This reduction is most likely
due to reduced sAPPalpha uptake but it might also be the result of
enhanced degradation.
We next asked, whether regulation of CDK5 expression by
sAPPalpha was also influenced by SORLA and if other proteins
associated with CDK5 function were altered after sAPPalpha
treatment. Western blot analysis of primary cortical neurons
treated with sAPPalpha revealed that CDK5 and the CDK5
Figure 1. Protein expression changes in neurons treated with sAPPalpha. (A) Prototypic two-dimensional polyacrylamid gel of proteins
extracted from primary cortical neurons stained with silver nitrate. Significant protein spot alterations in response to sAPPalpha treatment (300 ng/
ml) for one hour (red circles), 48 hours (blue circles) or in both treatment conditions (green circles) are indicated (n = 6 biological replicates per
genotype; paired Student’s t-test p,0.05). Gene names of identified proteins altered in both treatment conditions are indicated at respective
positions. (B) Magnification of gel region containing cyclin-dependent kinase 5 (CDK5). CDK5 is indicated in the non-treated (control) and treated
(sAPPalpha) condition. (C) Western blots of CDK5 in primary cortical neurons treated with sAPPalpha for one hour or 48 hours, respectively. Treated
neurons (sAPPalpha) show reduced expression levels of CDK5 as compared to control neurons (control). Actin served as loading control.
doi:10.1371/journal.pone.0065920.g001
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adaptor protein p25 (but not the CDK5 adaptor p35) were
significantly down-regulated in wild-type neurons after treatment
with sAPPalpha for one hour (Mann-Whitney-U test, p#0.05,
n = 6). As p25 is generated from p35 by calpain-dependent
cleavage, we also quantified p25/p35 ratios. Also, the ratio of
p25/p35 was significantly down-regulated (Figure 3 A & B).
One of the CDK5 target proteins identified in the proteome
screen to be significantly regulated upon sAPPalpha treatment was
collapsin-response mediator protein 2 (CRMP2). CRMP2 is
phosphorylated by CDK5 at Ser522 [33]. Analyzing the
phosphorylation state of CRMP2 upon sAPPalpha addition
revealed reduced CDK5 activity as phosphorylation of CRMP2
at Ser522 was significantly reduced in treated neurons (Mann-
Whitney-U test, p#0.05, n= 6).
In contrast, CDK5 was not significantly altered in Sorl1-
deficient neurons after sAPPalpha treatment (Figure 3 A & B). The
same finding was seen for expression of the CDK5-target
phospho-CRMP2 (Ser522) and the CDK5 adaptor proteins p35
and p25 (Mann-Whitney-U test, p#0.05, n= 6, Figure 3 A & B).
Reduction of phospho-CRMP2 (Ser522) was also observed in non-
treated Sorl1-deficient as compared to non-treated control
neurons. This could be due to the fact that sAPPalpha levels are
per se enhanced in Sorl1-deficient neurons due to altered APP
processing [34].
Together, our results revealed that the expression of CDK5 and
CDK5 associated proteins was altered after sAPPalpha treatment
in neurons. Reduced phosphorylation of CRMP documented
impaired CDK5 activity after sAPPalpha application. None of
these alterations were detected in Sorl1-deficient neurons proving
that SORLA is an essential sAPPalpha receptor.
Induction of Neuroprotective ORP150 by sAPPalpha
Up-regulation of ORP150 was previously shown to protect
neurons from hypoxia and excitotoxicity [35,36]. Interestingly,
expression of ORP150 was induced by sAPPalpha treatment
under both treatment conditions (1 hour and 48 hours of
treatment; Table S1). ORP150 might therefore be involved in
sAPPalpha-mediated neuroprotection.
Western blot analysis of neurons treated with sAPPalpha
confirmed significant up-regulation of ORP150 after sAPPalpha
Table 1. CDK5 associated proteins significantly altered in expression after treatment of neurons with sAPPalpha (1 h, 48 h indicate
duration of treatment; q up-regulation, Q down-regulation, ratio treated/control).
Treatment
condition
Direction of
regulation Gene name Protein name Comments
1 h, 48 h q (1.34);
q (1.37; 1.64);
q (1.52)
Crmp1;
Dpysl2;
Dpysl4
Dihydropyrimidinase-related
protein/Collapsin-response
mediator protein
Collapsin-response mediator proteins (CRMPs) are involved in apoptosis/
proliferation, cell migration, and differentiation. CRMP2 binds to
microtubules and regulates axon outgrowth in neurons. This action is
regulated by phosphorylation (via CDK5- and other kinases) at sites
hyperphosphorylated in Alzheimer disease [29,35]. CRMPs are altered in
expression after treatment of neurons with CDK5 inhibitor [38].
1 h, 48 h Q (0.52; 0.6; 0.61);
q,Q (0.83; 1.38)
Hist1h2ba;
Hist1h4a
Histone H2B type 1-A;
Histone H4
CDK5 phosphorylates a component of the histone deacetylase complex and
thus regulates histone acetylation i.e. during neuronal cell death. CDK5 can
also directly phosphorylates histones [31,51].
48 h Q (0.8) Stxbp1 Syntaxin-binding protein 1
(Munc18-1)
CDK5 promotes Munc18-1 phosphorylation and calcium-dependent
exocytosis [52].
48 h q (1.23; 1.35) Cbx3 Chromobox protein
homolog 3
Also known as HP1gamma; repressor of E2F-dependent transcription which
is regulated by CDK5 in the nucleus [53,54].
1 h, 48 h Q (0.71);
Q (0.79; 0.81; 0.59)
Tubb2a;
Tubb2b
Tubulin beta-2A chain;
Tubulin beta-2B chain
CDK5 phosphorylates several tubulin associated proteins regulating tubulin
dynamics [32]. CDK5 inhibition alters tubulin expression in neurons [39].
1 h q (1.32);
Q (0.69); q (1.31)
Ina; Myh10;
Npm1
Alpha-Internexin;
Myosin-10; Nucleophosmin
CDK5 phosphorylation targets [55,56]. The intermediate-filament protein
alpha-internexin was altered in neurons after CDK5 inhibition [38].
doi:10.1371/journal.pone.0033417.t001
Figure 2. Reduced uptake of sAPPalpha in SORLA-deficient neurons. Quantification of human, recombinant sAPPalpha in primary cortical
neurons either non-treated (control) or treated with 300 ng/ml sAPPalpha for 1 h using Western blotting (A) and densitometric scanning of replicate
blots (B). Sorl12/2 neurons show reduced levels sAPPalpha after one hour of treatment compared with wild-type cells (wt; n = 8, Mann-Whitney U
test). Actin served as loading control.
doi:10.1371/journal.pone.0065920.g002
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treatment of neurons. Again, this effect was not observed in
neurons lacking the sAPPalpha receptor SORLA (Mann-
Whitney-U test, p#0.05, n= 6; Figure 4 A & B). Together,
ORP150, a potential effector protein of sAPPalpha in neurons,
was induced after sAPPalpha treatment. This effect was
SORLA-dependent.
Discussion
The APP cleavage product sAPPalpha is considered to be
neurotrophic and neuroprotective [6–11,24,25]. Thus, loss of
sAPPalpha activity in AD patients might contribute to disease
pathology. However, little is known about molecular pathways
underlying these effects. Using a 2-DE based proteomic approach,
we uncovered that sAPPalpha significantly reduces expression and
activity of CDK5 and influences expression of CDK5 target
proteins in neurons. Interestingly, many of these CDK5 target
proteins (cofilin, beta-tubulin, alpha-internexin and CRMP;
table 1) were shown before to be altered in neurons treated with
CDK5 inhibitors [37,38]. This finding further supports a role of
sAPPalpha in regulating CDK5 signaling.
CDK5 is an atypical cyclin kinase as -in contrast to other
cyclin kinases- it inhibits the cell cycle to keep neurons in their
post-mitotic stage. Transfer of CDK5 out of the nucleus induces
neurodegeneration [39]. CDK5 also regulates neuronal mor-
phology via phosphorylation of central components of the
cellular cytoskeleton, such as tubulin, and tau [40]. Because
CDK5 phosphorylates tau, APP, and BACE1, a component of
the beta-secretase, CDK5 is an important link between amyloid-
and tau-pathology [31]. Regulation of CDK5 activity by
sAPPalpha was suggested before, as overexpression of sAPPal-
pha inhibited glutamate-induced CDK5 activation in N2a cells
[41]. In contrast to sAPPalpha, Abeta activates CDK5 (reviewed
in [42]). Aberrant activation of CDK5 can lead to collapse of
the synaptic cytoskeleton [43]. sAPPalpha potentially protects
from this collapse, as it maintains synaptic integrity [44].
Together, regulation of CDK5 activity in neurons might be the
most important determinant of how the two alternative APP
cleavage products Abeta and sAPPalpha counteract each other.
We also identified expression changes of the CDK5
phosphorylation target CRMP2 in neurons treated with
sAPPalpha. Interestingly, CRMP2 phosphorylation impairs
Figure 3. Reduction of CDK5 activity in neurons treated with sAPPalpha is SORLA-dependent. Quantification of CDK5, CDK5-target
phospho-CRMP2, total CRMP2, and CDK5-adaptor proteins p35 and p25 in primary cortical neurons either non-treated (control) or treated with
300 ng/ml sAPPalpha for 1 h using Western blotting (A) and densitometric scanning of replicate blots (B). In wild- type neurons (wt), CDK5, p25 and
phospho-CRMP2 (p-CRMP2) were significantly down-regulated after sAPPalpha treatment. Sorl12/2 neurons show no altered levels of the same
proteins after one hour of sAPPalpha treatment (n = 6, Mann-Whitney U test). Actin served as loading control.
doi:10.1371/journal.pone.0065920.g003
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neurite outgrowth, an effect that can be reversed by inhibition
of CDK5 [45]. We observed reduced phosphorylation of
CRMP2 at the CDK5-dependent phosphorylation site (Ser522)
in neurons treated with sAPPalpha. We further identified down-
regulation of p25 after sAPPalpha treatment of neurons. p25 is
a CDK5 adaptor protein that accumulates in the brains of AD
patients leading to abnormal CDK5 activation and hyperpho-
sphorylation of CDK5 targets, such as tau and CRMP2 [27,42].
Together, down-regulation of p25 and phospho-CRMP2 dem-
onstrate reduced activity of CDK5 in sAPPalpha treated
neurons and further support the important role of sAPPalpha
as neuroprotective factor.
One downstream effector protein providing neuroprotection
might be ORP150, a protein induced in neurons after
sAPPalpha treatment. ORP150 is an endoplasmic reticulum
associated chaperone. Interestingly, induction of ORP150
protein has been demonstrated before in cultured neurons
under hypoxic and excitotoxic stress conditions and in the
brains of patients who died of epileptic seizures. However,
overexpression of ORP150 protected neurons from hypoxia-
induced cell death and mediated higher resistance of mice
towards cerebral ischemia demonstrating that ORP150 protect-
ed cells from excitotoxicity [35,36]. Interestingly, sAPPalpha has
been reported to protect neurons from excitotoxicity as well
[41]. Based on our findings we now speculate that induction of
ORP150 by sAPPalpha might mediate this effect.
Finally, we provide functional evidence concerning the impor-
tance of SORLA as sAPPalpha receptor mediating not only
uptake of sAPPalpha, but also controlling regulation of down-
stream sAPPalpha targets. Direct binding of SORLA to
sAPPalpha and uptake of sAPPalpha by SORLA was shown
before [16,17]. We now document that SORLA is essential for the
molecular function of sAPPalpha, as regulation of CDK5,
phospho-CRMP2, p25 and ORP150 was no longer evident in
neurons deficient for SORLA. As SORLA itself is considered an
important genetic risk factor in AD [46] and low levels of this
receptor have been documented in AD patients [47], it is likely
that part of the neuroprotective properties ascribed to SORLA are
related to its function as sAPPalpha receptor. Concerning its
neuroprotective capabilities, so far SORLA was mainly recognized
for its ability to regulate APP processing in the first place
[20,34,48], but based in findings in this study SORLA might also
serve as receptor of APP processing products controlling their
respective cellular functions. That is at least the case for
sAPPalpha.
Conclusion
Our study provides insight into the molecular pathways
downstream of sAPPalpha in neurons. We identified CDK5 and
ORP150 as potential mediators of sAPPalpha-dependent neuro-
protection. Moreover, we demonstrate a central role for SORLA
as the sAPPalpha receptor; loss of sAPPalpha function in AD is a
plausible mechanism of loss of sAPPalpha function in AD [44].
Here, we provide a proteomic-based evidence of how APP
processing regulates neuronal function. We further propose that
proteins regulated by sAPPalpha might be potential drug targets in
their own right.
Supporting Information
Table S1 Proteins identified as significantly altered in expression
after 1 h or 48 h incubation with sAPPalpha. Proteins altered in
both treatment conditions (1 h and 48 h) are highlighted in grey.
(PDF)
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